EN DE
Watch Beijing Biostar Pharms Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Beijing Biostar Pharms Co Ltd (2563) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Beijing Biostar Pharms Co Ltd stock HK$2.76, price HK$3.49, that is 20.9% below the price, quality 48 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

BB Beijing Biostar Pharms Co Ltd logo Thin data Nov 10, 2026

Beijing Biostar Pharms Co Ltd

2563 · HK

Expensive (fair value 21% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Ranks above peers (6/9) 
Revenue last quarter +148% vs. a year ago. 
Quality 48/100 
Fair value HK$2.76 · Overvalued 
Weak Growth (revenue 3y −0.2 %/yr in CNY) 
Loss-making · -188.3% net margin (TTM) 
Negative free cash flow 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Beijing Biostar Pharms Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$35.45 HK$2.63 Fair Value HK$2.76 Oct 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

24‑month range HK$2.63 – HK$35.45 · fair‑value band HK$2.07 – HK$3.46 · the HK$3.49 price screens above the HK$2.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Beijing Biostar Pharms Co in your weekly email

Every Wednesday you see whether Beijing Biostar Pharms Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People's Republic of China.

Show moreShow less

The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications; and Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant intensive, first line gastric cancer, platinum-resistant ovarian cancer, and soft tissue sarcoma indications.

It is also involved in the development of Utidelone antibody drug conjugate in preclinical studies; and BG22, BG18, and BG44 products for solid tumor indications in preclinical studies. Beijing Biostar Pharmaceuticals Co., Ltd. was incorporated in 2002 and is headquartered in Beijing, China.

Stock analysis

Beijing Biostar Pharms Co Ltd (2563) currently trades at HK$3.49, while our estimate is HK$2.76, 21% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$2.07 (bear) to HK$3.46 (bull), the price of HK$3.49 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Beijing Biostar Pharms Co Ltd reported revenue of 37.1M CNY in FY2025 versus 107M CNY in FY2021, a compound −23.2%/yr. Reported net income was −143M CNY in FY2025.

Key figures

Market cap HK$1.3B (≈ $165M) Micro · P/S ratio 25.4 · Return on equity −15.0% · Return on assets (EBIT) −23.0% (5-year average) · Operating margin −54.2% · Revenue (TTM) 55.2M CNY · Revenue growth (YoY) +148% · Free cash flow −175M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −21%, 2563 screens richer than that median.

Fair Value

Bear HK$2.07 Fair Value HK$2.76 Bull HK$3.46
Price HK$3.49 · Downside -20.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 35
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 74
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 37
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 4/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−52.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−385.5% (2021) → −407.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2563 screens overvalued: fair value 21% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Beijing Biostar Pharms Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 48 · Above median
Fair Value upside −20.9% · Above median
Profitability
Return on assets −16.6% · Above median
Net margin (12 months) −188.3% · Bottom 25%
Operating margin (12 months) −54.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 147.8% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.48× · Cheaper than median
P/S (12 months) 19.89× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)5 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 2563
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 2563
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs 2563
Genmab A/S GMAB kr 3,448 kr 3,793 +10% vs 2563
argenx SE ARGX $960.04 $908.40 −5% vs 2563
CSL Limited CSL A$202.52 A$185.51 −8% vs 2563
Moderna, Inc MRNA $223.37 $139.99 −37% vs 2563
Revolution Medicines, Inc RVMD $172.29 $88.78 −48% vs 2563
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 2563
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 2563

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beijing Biostar Pharms Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Beijing Biostar Pharms Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2563

Frequently asked questions

Is Beijing Biostar Pharms Co Ltd (2563) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$2.76 versus a price of HK$3.49, about 21% lower (overvalued).
What is the fair value of 2563?
Our estimate for Beijing Biostar Pharms Co Ltd is HK$2.76 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$3.49.
What is the quality score of 2563?
Beijing Biostar Pharms Co Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Biostar Pharms Co Ltd (2563)?
Our calculated price target is the estimate of HK$2.76 (as of Nov 10, 2026). Cautious scenario HK$2.07, optimistic scenario HK$3.46. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Beijing Biostar Pharms Co Ltd stock forecast for 2026?
Our estimate puts fair value at HK$2.76, about 21% lower versus a price of HK$3.49 (overvalued). Cautious scenario HK$2.07, optimistic scenario HK$3.46. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Biostar Pharms Co Ltd (2563)?
Beijing Biostar Pharms Co Ltd reported trailing-twelve-month revenue of about 55.2M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Beijing Biostar Pharms Co Ltd (2563)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Biostar Pharms Co Ltd it is HK$2.76 per share (as of Nov 10, 2026), against a price of HK$3.49.
Is Beijing Biostar Pharms Co Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2563 trades above its calculated fair value: price HK$3.49, fair value HK$2.76, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2563?
No. The price is what the market pays today (HK$3.49); the fair value is what the company's own numbers justify (HK$2.76). For Beijing Biostar Pharms Co Ltd the two are HK$0.7300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Biostar Pharms Co Ltd worth?
The market values Beijing Biostar Pharms Co Ltd at about HK$1.3B (market capitalisation, as of Nov 10, 2026). Per share that is HK$3.49; our models calculate a fair value of HK$2.76 per share.
What do the bullish and bearish scenarios say about 2563?
Our models span a range for Beijing Biostar Pharms Co Ltd: cautious scenario HK$2.07, base HK$2.76, optimistic HK$3.46 per share (as of Nov 10, 2026, price HK$3.49). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Beijing Biostar Pharms Co Ltd (2563)?
Balance-sheet figures for Beijing Biostar Pharms Co Ltd (as of Nov 10, 2026): return on equity −15.0%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 2563 from its 52-week high?
Beijing Biostar Pharms Co Ltd trades at HK$3.49, about 29% below its 52-week high of HK$4.89 and 33% above the low of HK$2.63 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.76 is for.
Which stocks are comparable to Beijing Biostar Pharms Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Biostar Pharms Co Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price HK$3.49, calculated fair value HK$2.76 (−21%), Quality Score 48/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Beijing Biostar Pharms Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Biostar Pharms Co Ltd (2563)?
The closing price on Nov 13, 2026 was HK$3.49. Our estimate is HK$2.76, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Biostar Pharms Co Ltd right now?
Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Beijing Biostar Pharms Co Ltd

How large is the market capitalisation of Beijing Biostar Pharms Co Ltd (2563)?
The market capitalisation of Beijing Biostar Pharms Co Ltd is HK$1.3B (≈ $165M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Biostar Pharms Co Ltd (2563)?
The price-to-sales ratio of Beijing Biostar Pharms Co Ltd is 25.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Beijing Biostar Pharms Co Ltd (2563)?
The return on equity (ROE) of Beijing Biostar Pharms Co Ltd is −15.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Biostar Pharms Co Ltd (2563)?
On an EBIT basis the return on assets of Beijing Biostar Pharms Co Ltd is −23.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Biostar Pharms Co Ltd (2563)?
The operating margin of Beijing Biostar Pharms Co Ltd is −54.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Biostar Pharms Co Ltd (2563)?
Revenue at Beijing Biostar Pharms Co Ltd is growing 148% versus a year earlier (3y avg −0.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Beijing Biostar Pharms Co Ltd (2563) generate?
The free cash flow of Beijing Biostar Pharms Co Ltd is −175M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Beijing Biostar Pharms Co Ltd (2563) hold?
Beijing Biostar Pharms Co Ltd holds more cash than debt, 506M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Beijing Biostar Pharms Co Ltd in the live analysis

One click puts Beijing Biostar Pharms Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.